India's Pharmaceutical Exports

Country Profile

Fiji

A growing Pacific Island destination for Indian pharmaceuticals — $8.6 million in FY 2025–26, with 3.4× growth over the past decade. Dominated by drug formulations and vaccines.

🇫🇯 #148 Destination · $8.6M · 3.4× growth since FY2015
Single-source profile. All data from DGCIS India export records (fiscal year, April–March). No partner-country import data available for Fiji.
$8.6M
Exports FY2025–26 DGCIS
3.4×
Growth FY2015→2026
0.03%
Share of India Total
#148
Rank Among 178 Markets
11.7%
CAGR FY2015→2026
Fiji is a small but steadily growing market for Indian pharmaceuticals. Exports have risen from $2.5 million in FY 2014–15 to $8.6 million in FY 2025–26 — a compound annual growth rate of 11.7%. Drug formulations account for over 76% of shipments, with vaccines emerging as the second-largest category at $1.1 million, reflecting India's role in supplying essential immunisation products to Pacific Island nations.
Export Trend DGCIS FY
Category Mix — FY 2025–26 DGCIS
Drug Formulations $6.55M (76.1%) Vaccines $1.06M (12.3%) Surgicals $0.66M (7.7%) AYUSH / Herbal $0.35M (4.0%)
Top 10 Products (HS8) — FY 2025–26 DGCIS
Indian Pharma Investment Source: RBI ODI Data

No recorded pharmaceutical sector investment transactions from Indian companies to Fiji in the RBI overseas direct investment dataset (2011–2026). As the trade relationship deepens, investment may follow — India's pharma companies typically establish distribution partnerships before committing to direct overseas investment.